Hepatic 11β-hydroxysteroid dehydrogenase type 1 activity in obesity and type 2 diabetes using a novel triple tracer cortisol technique

Aims/hypothesis Dysregulation of 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD) enzyme activities are implicated in the pathogenesis of obesity and insulin resistance. The aim of the study was to determine whether hepatic 11 beta-HSD type 1 (11 beta-HSD-1) enzyme activity differs in people with and without obesity and type 2 diabetes. Methods We measured hepatic 11 beta-HSD-1 activity in the overnight fasted state in 20 lean non-diabetic participants (LND), 21 overweight/obese non-diabetic participants (OND) and 20 overweight/obese participants with type 2 diabetes (ODM) using a non-invasive approach. One mg doses of [9,12,12-H-2(3)]cortisol (D cortisol) and [4-C-13]cortisone ([C-13]cortisone) were ingested, while [1,2,6,7-H-3]cortisol ([H-3] cortisol) was infused intravenously to enable concurrent measurements of first-pass hepatic extraction of ingested D cortisol and hepatic conversion of ingested [C-13]cortisone to C13 cortisol derived from the ingested cortisone (a measure of 11 beta-HSD-1 activity in the liver) using an isotope dilution technique. One-way ANOVA models and Kruskal-Wallis tests were used to test the hypothesis. Results Plasma D cortisol and C13 cortisol concentrations were lower in OND than in LND (p<0.05) over 6 h of the study. There was no difference (p=0.15) in C13 and D cortisol concentrations between OND and ODM and between LND and ODM for the same study period. Hepatic conversion of [C-13]cortisone to C13 cortisol was similar between groups. Conclusions/interpretation Hepatic conversion of [C-13]cortisone to C13 cortisol did not differ between the groups studied. We conclude that hepatic 11 beta-HSD-1 activity is similar in individuals who are overweight/obese or who have type 2 diabetes.